| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.
|
Arthritis Care Res (Hoboken)
|
2012
|
5.22
|
|
2
|
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.
|
Arthritis Care Res (Hoboken)
|
2012
|
2.83
|
|
3
|
Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice.
|
N Z Med J
|
2012
|
2.37
|
|
4
|
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria.
|
J Rheumatol
|
2013
|
1.77
|
|
5
|
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
|
Arthritis Rheum
|
2012
|
1.54
|
|
6
|
The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease.
|
Respirology
|
2012
|
1.49
|
|
7
|
Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
|
J Rheumatol
|
2013
|
1.45
|
|
8
|
A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets.
|
Hum Mol Genet
|
2010
|
1.33
|
|
9
|
Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case-control sample sets.
|
Arthritis Rheum
|
2009
|
1.32
|
|
10
|
Association of variation in Fcgamma receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples.
|
Ann Rheum Dis
|
2010
|
1.31
|
|
11
|
National prevalence of gout derived from administrative health data in Aotearoa New Zealand.
|
Rheumatology (Oxford)
|
2012
|
1.30
|
|
12
|
The gouty tophus: a review.
|
Curr Rheumatol Rep
|
2015
|
1.26
|
|
13
|
Outcome domains for studies of acute and chronic gout.
|
J Rheumatol
|
2009
|
1.24
|
|
14
|
The genetic basis of hyperuricaemia and gout.
|
Joint Bone Spine
|
2010
|
1.20
|
|
15
|
Developing a provisional definition of flare in patients with established gout.
|
Arthritis Rheum
|
2012
|
1.10
|
|
16
|
'Choosing shoes': a preliminary study into the challenges facing clinicians in assessing footwear for rheumatoid patients.
|
J Foot Ankle Res
|
2010
|
1.08
|
|
17
|
The renal urate transporter SLC17A1 locus: confirmation of association with gout.
|
Arthritis Res Ther
|
2012
|
1.08
|
|
18
|
Clinical audit of foot problems in patients with rheumatoid arthritis treated at Counties Manukau District Health Board, Auckland, New Zealand.
|
J Foot Ankle Res
|
2009
|
1.07
|
|
19
|
Progress in measurement instruments for acute and chronic gout studies.
|
J Rheumatol
|
2009
|
1.06
|
|
20
|
Imaging in gout--what can we learn from MRI, CT, DECT and US?
|
Arthritis Res Ther
|
2011
|
1.06
|
|
21
|
Functional and biomechanical characteristics of foot disease in chronic gout: A case-control study.
|
Clin Biomech (Bristol, Avon)
|
2010
|
1.00
|
|
22
|
Foot pain, impairment, and disability in patients with acute gout flares: A prospective observational study.
|
Arthritis Care Res (Hoboken)
|
2012
|
0.99
|
|
23
|
Imaging of gout: findings and utility.
|
Arthritis Res Ther
|
2009
|
0.98
|
|
24
|
The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach.
|
J Clin Rheumatol
|
2011
|
0.98
|
|
25
|
A review of uric acid, crystal deposition disease, and gout.
|
Adv Ther
|
2014
|
0.97
|
|
26
|
Predicting joint damage in rheumatoid arthritis using MRI scanning.
|
Arthritis Res Ther
|
2009
|
0.97
|
|
27
|
Gout--what are the treatment options?
|
Expert Opin Pharmacother
|
2009
|
0.94
|
|
28
|
Bone erosions in patients with chronic gouty arthropathy are associated with tophi but not bone oedema or synovitis: new insights from a 3 T MRI study.
|
Rheumatology (Oxford)
|
2013
|
0.93
|
|
29
|
Characterization of new bone formation in gout: a quantitative site-by-site analysis using plain radiography and computed tomography.
|
Arthritis Res Ther
|
2012
|
0.93
|
|
30
|
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
|
J Rheumatol
|
2011
|
0.92
|
|
31
|
Assessment of cartilage loss at the wrist in rheumatoid arthritis using a new MRI scoring system.
|
Ann Rheum Dis
|
2010
|
0.92
|
|
32
|
Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance.
|
Arthritis Res Ther
|
2010
|
0.92
|
|
33
|
Magnetic resonance imaging bone edema is not a major feature of gout unless there is concomitant osteomyelitis: 10-year findings from a high-prevalence population.
|
J Rheumatol
|
2011
|
0.92
|
|
34
|
New insights into an old disease: advanced imaging in the diagnosis and management of gout.
|
Postgrad Med J
|
2012
|
0.91
|
|
35
|
The effects of commercially available footwear on foot pain and disability in people with gout: a pilot study.
|
BMC Musculoskelet Disord
|
2013
|
0.90
|
|
36
|
Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption.
|
Arthritis Res Ther
|
2013
|
0.89
|
|
37
|
Quadriceps arthrogenic muscle inhibition: the effects of experimental knee joint effusion on motor cortex excitability.
|
Arthritis Res Ther
|
2014
|
0.89
|
|
38
|
Prevalence and clinical factors associated with gout in patients with diabetes and prediabetes.
|
Rheumatology (Oxford)
|
2011
|
0.89
|
|
39
|
Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects.
|
Arthritis Res Ther
|
2013
|
0.89
|
|
40
|
Mechanisms of joint damage in gout: evidence from cellular and imaging studies.
|
Nat Rev Rheumatol
|
2012
|
0.89
|
|
41
|
Obstacles to action in arthritis: a community case-control study.
|
Int J Rheum Dis
|
2009
|
0.88
|
|
42
|
Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials.
|
J Rheumatol
|
2011
|
0.88
|
|
43
|
DECT urate deposits: now you see them, now you don't.
|
Ann Rheum Dis
|
2012
|
0.87
|
|
44
|
The PTPN22 locus and rheumatoid arthritis: no evidence for an effect on risk independent of Arg620Trp.
|
PLoS One
|
2010
|
0.87
|
|
45
|
Influence of HLA-B27 on the clinical presentation of psoriatic arthritis.
|
J Rheumatol
|
2003
|
0.87
|
|
46
|
Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis.
|
Respir Med
|
2012
|
0.86
|
|
47
|
Effects of cryotherapy on arthrogenic muscle inhibition using an experimental model of knee swelling.
|
Arthritis Rheum
|
2009
|
0.86
|
|
48
|
The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity.
|
Arthritis Res Ther
|
2011
|
0.86
|
|
49
|
Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study.
|
Ann Rheum Dis
|
2011
|
0.86
|
|
50
|
High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors.
|
N Z Med J
|
2008
|
0.86
|
|
51
|
Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.
|
Semin Arthritis Rheum
|
2010
|
0.86
|
|
52
|
Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout.
|
Ann Rheum Dis
|
2011
|
0.86
|
|
53
|
Factors associated with recurrent hospital admissions for gout: a case-control study.
|
J Clin Rheumatol
|
2009
|
0.85
|
|
54
|
Footwear characteristics and factors influencing footwear choice in patients with gout.
|
Arthritis Care Res (Hoboken)
|
2011
|
0.85
|
|
55
|
Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout.
|
Arthritis Rheumatol
|
2014
|
0.85
|
|
56
|
The effects of monosodium urate monohydrate crystals on chondrocyte viability and function: implications for development of cartilage damage in gout.
|
J Rheumatol
|
2013
|
0.85
|
|
57
|
Measuring bone erosion and edema in rheumatoid arthritis: a comparison of manual segmentation and RAMRIS methods.
|
J Magn Reson Imaging
|
2011
|
0.84
|
|
58
|
Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset.
|
Rheumatology (Oxford)
|
2012
|
0.84
|
|
59
|
Advances in pharmacotherapy for the treatment of gout.
|
Expert Opin Pharmacother
|
2014
|
0.83
|
|
60
|
Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study.
|
Arthritis Res Ther
|
2013
|
0.83
|
|
61
|
Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge.
|
Arthritis Res Ther
|
2014
|
0.83
|
|
62
|
Podiatry services for patients with arthritis: an unmet need.
|
N Z Med J
|
2010
|
0.82
|
|
63
|
Management of gout in primary care: challenges and potential solutions.
|
Rheumatology (Oxford)
|
2013
|
0.82
|
|
64
|
Outcome evaluations in gout.
|
J Rheumatol
|
2007
|
0.82
|
|
65
|
Quantifying synovitis in rheumatoid arthritis using computer-assisted manual segmentation with 3 Tesla MRI scanning.
|
J Magn Reson Imaging
|
2011
|
0.82
|
|
66
|
Debunking the myths to provide 21st Century management of gout.
|
N Z Med J
|
2008
|
0.81
|
|
67
|
No evidence for association of the systemic lupus erythematosus-associated ITGAM variant, R77H, with rheumatoid arthritis in the Caucasian population.
|
Rheumatology (Oxford)
|
2009
|
0.81
|
|
68
|
MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage.
|
Arthritis Res Ther
|
2009
|
0.80
|
|
69
|
The ITGAV rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets.
|
Arthritis Res Ther
|
2009
|
0.79
|
|
70
|
Do patient preferences for core outcome domains for chronic gout studies support the validity of composite response criteria?
|
Arthritis Care Res (Hoboken)
|
2013
|
0.79
|
|
71
|
Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.
|
J Rheumatol
|
2014
|
0.79
|
|
72
|
Reliability of the TekScan MatScan® system for the measurement of postural stability in older people with rheumatoid arthritis.
|
J Foot Ankle Res
|
2012
|
0.79
|
|
73
|
Colchicine prescribing and safety monitoring in patients with gout.
|
N Z Med J
|
2007
|
0.79
|
|
74
|
MRI osteitis predicts cartilage damage at the wrist in RA: a three-year prospective 3T MRI study examining cartilage damage.
|
Arthritis Res Ther
|
2014
|
0.79
|
|
75
|
Is serum urate causally associated with incident cardiovascular disease?
|
Rheumatology (Oxford)
|
2012
|
0.78
|
|
76
|
Toward development of a Tophus Impact Questionnaire: a qualitative study exploring the experience of people with tophaceous gout.
|
J Clin Rheumatol
|
2014
|
0.77
|
|
77
|
MRI in psoriatic arthritis: insights into pathogenesis and treatment response.
|
Curr Rheumatol Rep
|
2008
|
0.77
|
|
78
|
Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers.
|
N Z Med J
|
2014
|
0.77
|
|
79
|
Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease.
|
Inflamm Bowel Dis
|
2015
|
0.77
|
|
80
|
Gastrointestinal disease and psoriatic arthritis.
|
J Rheumatol
|
2004
|
0.77
|
|
81
|
Complementary and alternative medicine use in patients with gout: a longitudinal observational study.
|
J Clin Rheumatol
|
2014
|
0.76
|
|
82
|
Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support.
|
N Z Med J
|
2008
|
0.76
|
|
83
|
The natural killer cell: a further innate mediator of gouty inflammation?
|
Immunol Cell Biol
|
2009
|
0.76
|
|
84
|
OMERACT endorsement of measures of outcome for studies of acute gout.
|
J Rheumatol
|
2013
|
0.76
|
|
85
|
Replication of association of the interleukin 23 receptor rs1343151 variant with rheumatoid arthritis in Caucasian sample sets.
|
Ann Rheum Dis
|
2011
|
0.76
|
|
86
|
Alcohol excess may be overemphasised in gout treated in secondary care.
|
N Z Med J
|
2006
|
0.75
|
|
87
|
Prevention of colchicine toxicity in patients with gout.
|
N Z Med J
|
2007
|
0.75
|
|
88
|
A human leukocyte antigen locus haplotype confers risk for allopurinol-related adverse effects in Caucasian patients with gout.
|
Pharmacogenet Genomics
|
2015
|
0.75
|
|
89
|
The relationship of apolipoprotein B and very low density lipoprotein triglyceride with hyperuricemia and gout.
|
Arthritis Res Ther
|
2014
|
0.75
|
|
90
|
Will Jill come tumbling after? The case for a JAK2-type mutation as a prequel to the connective tissue disorders.
|
Med Hypotheses
|
2009
|
0.75
|
|
91
|
Angiotensin receptor blockers ameliorate collagen-induced arthritis in mice: comment on the article by Sagawa et al.
|
Arthritis Rheum
|
2005
|
0.75
|
|
92
|
The Work Instability Scale predicts absenteeism in people with gout and suggests a higher risk for those in manual occupations.
|
J Clin Rheumatol
|
2012
|
0.75
|
|
93
|
In defense of research into the crystal induced arthropathies.
|
J Rheumatol
|
2008
|
0.75
|
|
94
|
Clarification of the modified radiographic damage scoring method for gout.
|
J Rheumatol
|
2012
|
0.75
|
|
95
|
No evidence for association of Chr 9p21 variant rs1333049 with gout in New Zealand case-control sample sets.
|
Rheumatology (Oxford)
|
2012
|
0.75
|
|
96
|
Analysis of association of DNASE2 promoter variation with rheumatoid arthritis in European Caucasians.
|
Ann Rheum Dis
|
2011
|
0.75
|
|
97
|
Crystal arthritis: a new 'package of care' strategy for effective gout management.
|
Nat Rev Rheumatol
|
2012
|
0.75
|
|
98
|
Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study.
|
Ann Rheum Dis
|
2013
|
0.75
|
|
99
|
An Illness by Any Other Name: The Effect of Renaming Gout on Illness and Treatment Perceptions.
|
Health Psychol
|
2017
|
0.75
|
|
100
|
Nurse-led cardiovascular disease risk management intervention for patients with gout.
|
Eur J Cardiovasc Nurs
|
2010
|
0.75
|
|
101
|
Anti-Citrullinated Peptide Antibodies in Tophaceous Gout: Prevalence in a Polynesian Population.
|
J Clin Rheumatol
|
2015
|
0.75
|
|
102
|
Clinical images: Transient regional osteoporosis.
|
Arthritis Rheum
|
2009
|
0.75
|
|
103
|
Quantifying bone marrow edema in the rheumatoid cervical spine using magnetic resonance imaging.
|
J Rheumatol
|
2010
|
0.75
|
|
104
|
More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial.
|
J Prim Health Care
|
2009
|
0.75
|
|
105
|
Evaluating intratester reliability of manual masking of plantar pressure measurements associated with chronic gout.
|
J Am Podiatr Med Assoc
|
2011
|
0.75
|
|
106
|
Colchicine prescribing in patients with gout.
|
N Z Med J
|
2011
|
0.75
|